NEW YORK, April 5 /PRNewswire/ -- Cardiovascular disease (CVD) is the
leading cause of death among dialysis patients, but the treatment for dialysis
patients with CVD is not as effective as it is in the general population,
according to new guidelines published by the National Kidney Foundation (NKF)
in a supplement to the April 2005 issue of the American Journal of Kidney
Diseases. The guidelines, Cardiovascular Disease in Dialysis Patients, warn
that CVD is also prevalent in the pediatric dialysis population, dialysis
patients are more prone to side-effects of treatment and that more research is
needed to help better manage CVD in dialysis patients. More than 300,000
Americans receive dialysis to treat kidney failure.
"This guideline highlights those aspects of CVD care that are different in
dialysis patients when compared to the general population," said Alfred K.
Cheung, M.D., co-chair of the NKF work group that developed the guideline.
"Because of these differences, practitioners cannot solely rely on existing
CVD guidelines for the general population to treat CVD in dialysis patients."
William Henrich, M.D., co-chair of the guideline work group, developed
through the NKF's Kidney Disease Outcomes Quality Initiative (K/DOQI),
highlighted key findings:
* Pediatric chronic dialysis patients are 1,000 times more likely to die
from CVD than the general pediatric population
* All dialysis units should have on-site capability for external cardiac
defibrillation, such as automatic external defibrillators
* Predialysis and postdialysis blood pressure goals should be less than
140/90 mm Hg and less than 130/80 mm Hg, respectively
* Dialysis patients often have CVD-related risk factors, including
anemia, hyperparathyroidism, hypoalbuminemia and chronic inflammation,
"CVD presents unique challenges to dialysis patients that significantly
impact longevity and quality of life," said Norman S. Coplon, chairman and
founder of Satellite Healthcare, primary sponsor of the guideline. "We are
proud to partner with the National Kidney Foundation to sponsor the
development of this guideline. We believe it will improve patient outcomes and
encourage sorely needed research."
Guideline Work Group
The NKF- K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in
Dialysis Patients are the culmination of two years' work reviewing evidence
published in peer-reviewed medical journals by 18 volunteer experts in
nephrology, cardiology, epidemiology, social work, nutrition, pediatrics,
pharmacology, nursing and internal medicine.
Satellite Healthcare is Primary Development Sponsor of the guideline.
Additional guideline sponsors include: Amgen and Genzyme Corporation. Amgen is
Founding and Principal Sponsor of NKF-K/DOQI. Sponsors are not involved in any
aspect of the actual guideline development process.
To obtain more information about the guideline, call the National Kidney
Foundation at (800) 622-9010 or (212) 889-2210, or visit http://www.kdoqi.org.
The National Kidney Foundation's Kidney Disease Outcomes Quality
Initiative (K/DOQI) provides evidence-based clinical practice guidelines
developed by volunteer physicians and health care providers for all phases of
kidney disease and related complications, from diagnosis to monitoring and
management. K/DOQI expands the Dialysis Outcomes Quality Initiative or DOQI, a
project begun by the National Kidney Foundation in 1995 and recognized
throughout the world for improving the care of dialysis patients. For more
information, please visit http://www.kdoqi.org.
About the National Kidney Foundation
The National Kidney Foundation is dedicated to preventing kidney and
urinary tract diseases, improving the health and well being of individuals and
families affected by these diseases, influencing public policy in support of
the kidney community and increasing the availability of all organs for
transplantation. For more information, please visit http://www.kidney.org.
SOURCE National Kidney Foundation